| D-09 Elisabeth Rouits Incorporating clinical utility and Pharmacokinetics (PK)/Pharmacodynamics (PD) in clinical development of oncology drug candidate with a Bayesian decision analysis perspective in the context of OPTIMUS initiative Friday 11:25-11:45 |
